Biogenesis of Weibel-Palade bodies in von Willebrand’s disease variants with impaired von Willebrand factor intrachain or interchain disulfide bond formation

Background Mutations of cysteine residues in von Willebrand factor are known to reduce the storage and secretion of this factor, thus leading to reduced antigen levels. However, one cysteine mutation, p.Cys2773Ser, has been found in patients with type 2A(IID) von Willebrand’s disease who have normal plasma levels of von Willebrand factor. We hypothesize that disruption of either intra- or interchain disulfide bonds by cysteine mutations in von Willebrand factor has different effects on the biogenesis of Weibel-Palade bodies. Design and Methods The effect of specific cysteine mutations that either disrupt intrachain (p.Cys1130Phe and p.Cys2671Tyr) or interchain (p.Cys2773Ser) disulfide bonds on storage and secretion of von Willebrand factor was studied by transient transfection of human embryonic kidney cell line 293. Upon expression of von Willebrand factor these cells formed endothelial Weibel-Palade body-like organelles called pseudo-Weibel-Palade bodies. Storage of von Willebrand factor was analyzed with both confocal immunofluorescence and electron microscopy. Regulated secretion of von Willebrand factor was induced by phorbol 12-myristate 13-acetate. Results p.Cys1130Phe and p.Cys2671Tyr reduced the storage of von Willebrand factor into pseudo-Weibel-Palade bodies with notable retention of von Willebrand factor in the endoplasmic reticulum, whereas p.Cys2773Ser-von Willebrand factor was stored normally. As expected, wild-type von Willebrand factor formed proteinaceous tubules that were seen under electron microscopy as longitudinal striations in pseudo-Weibel-Palade bodies. p.Cys2773Ser caused severe defects in von Willebrand factor multimerization but the factor formed normal tubules. Furthermore, the basal and regulated secretion of von Willebrand factor was drastically impaired by p.Cys1130Phe and p.Cys2671Tyr, but not by p.Cys2773Ser. Conclusions We postulate that natural mutations of cysteines involved in the formation of interchain disulfide bonds do not affect either the storage in Weibel-Palade bodies or secretion of von Willebrand factor, whereas mutations of cysteines forming intrachain disulfide bonds lead to reduced von Willebrand factor storage and secretion because the von Willebrand factor is retained in the endoplasmic reticulum.

[1]  T. Walz,et al.  A pH‐regulated dimeric bouquet in the structure of von Willebrand factor , 2011, The EMBO journal.

[2]  T. Springer,et al.  Biology and physics of von Willebrand factor concatamers , 2011, Journal of thrombosis and haemostasis : JTH.

[3]  P. Reitsma,et al.  Intracellular Storage and Regulated Secretion of Von Willebrand Factor in Quantitative Von Willebrand Disease* , 2011, The Journal of Biological Chemistry.

[4]  J. Sadler,et al.  Phylogenetic and Functional Analysis of Histidine Residues Essential for pH-dependent Multimerization of von Willebrand Factor*♦ , 2011, The Journal of Biological Chemistry.

[5]  J. Voorberg,et al.  Functional architecture of Weibel-Palade bodies. , 2011, Blood.

[6]  R. Schneppenheim,et al.  A cluster of mutations in the D3 domain of von Willebrand factor correlates with a distinct subgroup of von Willebrand disease: type 2A/IIE. , 2010, Blood.

[7]  P. Rosenthal,et al.  Structural organization of Weibel-Palade bodies revealed by cryo-EM of vitrified endothelial cells , 2009, Proceedings of the National Academy of Sciences.

[8]  J. Goudemand,et al.  Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM‐1VWD study , 2009, Journal of Thrombosis and Haemostasis.

[9]  L. Hewlett,et al.  Basal secretion of von Willebrand factor from human endothelial cells. , 2008, Blood.

[10]  J. Goudemand,et al.  Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM‐1VWD) , 2008, Journal of thrombosis and haemostasis : JTH.

[11]  A. Tosetto,et al.  Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. , 2008, Blood.

[12]  A. Koster,et al.  A new look at Weibel-Palade body structure in endothelial cells using electron tomography. , 2008, Journal of structural biology.

[13]  E. Egelman,et al.  Assembly of Weibel–Palade body-like tubules from N-terminal domains of von Willebrand factor , 2008, Proceedings of the National Academy of Sciences.

[14]  Luke T. Dang,et al.  Two Cys residues essential for von Willebrand factor multimer assembly in the Golgi , 2007, Proceedings of the National Academy of Sciences.

[15]  J. Voorberg,et al.  Differential effects of the loss of intrachain- versus interchain-disulfide bonds in the cystine-knot domain of von Willebrand factor on the clinical phenotype of von Willebrand disease , 2006, Thrombosis and Haemostasis.

[16]  R. Bertina,et al.  Homozygous C2362F von Willebrand factor induces intracellular retention of mutant von Willebrand factor resulting in autosomal recessive severe von Willebrand disease , 2006, British journal of haematology.

[17]  É. Fressinaud,et al.  Mutations C1157F and C1234W of von Willebrand factor cause intracellular retention with defective multimerization and secretion , 2006, Journal of thrombosis and haemostasis : JTH.

[18]  P. Lenting,et al.  Cysteine‐mutations in von Willebrand factor associated with increased clearance , 2005, Journal of thrombosis and haemostasis : JTH.

[19]  R. Bertina,et al.  Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues , 2004, Journal of thrombosis and haemostasis : JTH.

[20]  D. Cutler,et al.  Analysis of intracellular storage and regulated secretion of 3 von Willebrand disease-causing variants of von Willebrand factor. , 2003, Blood.

[21]  M. Rondaij,et al.  Real-Time Imaging of the Dynamics and Secretory Behavior of Weibel-Palade Bodies , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[22]  J. Eikenboom,et al.  Type 1 von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible general mechanism for dominant mutations of oligomeric proteins. , 2001, Blood.

[23]  K. Pasi,et al.  Aberrant dimerization of von Willebrand factor as the result of mutations in the carboxy-terminal region: identification of 3 mutations in members of 3 different families with type 2A (phenotype IID) von Willebrand disease. , 2001, Blood.

[24]  A. Goodeve,et al.  Endoplasmic reticulum retention and prolonged association of a von Willebrand's disease-causing von Willebrand factor variant with ERp57 and calnexin. , 2001, Biochemical and biophysical research communications.

[25]  I. Braakman,et al.  The CXXCXXC motif determines the folding, structure and stability of human Ero1‐Lα , 2000, The EMBO journal.

[26]  J. Sadler,et al.  Localization of Disulfide Bonds in the Cystine Knot Domain of Human von Willebrand Factor* , 2000, The Journal of Biological Chemistry.

[27]  R. Bertina,et al.  Characterization of the Genetic Defects in Recessive Type 1 and Type 3 von Willebrand Disease Patients of Italian Origin , 1998, Thrombosis and Haemostasis.

[28]  R. Angeletti,et al.  Localization of Endogenous Furin in Cultured Cell Lines , 1997, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[29]  P. Reitsma,et al.  Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor. , 1996, Blood.

[30]  J. Ware,et al.  Defective dimerization of von Willebrand factor subunits due to a Cys-> Arg mutation in type IID von Willebrand disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  I. Rabinowitz,et al.  New variant of von Willebrand disease type II with markedly increased levels of von Willebrand factor antigen and dominant mode of inheritance: von Willebrand disease type IIC Miami. , 1993, Blood.

[32]  J. V. van Mourik,et al.  Assembly and routing of von Willebrand factor variants: the requirements for disulfide-linked dimerization reside within the carboxy-terminal 151 amino acids , 1991, The Journal of cell biology.

[33]  A. Brake,et al.  Expression of a human proprotein processing enzyme: correct cleavage of the von Willebrand factor precursor at a paired basic amino acid site. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[34]  R. Siezen,et al.  Furin is a subtilisin-like proprotein processing enzyme in higher eukaryotes , 1990, Molecular Biology Reports.

[35]  K. Titani,et al.  Identification of disulfide-bridged substructures within human von Willebrand factor. , 1987, Biochemistry.

[36]  D. Wagner,et al.  Inducible secretion of large, biologically potent von Willebrand factor multimers , 1986, Cell.

[37]  J. Goudemand,et al.  Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). , 2007, Blood.

[38]  Sandra L Haberichter,et al.  Re-establishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells. , 2005, Blood.

[39]  F. Cohen,et al.  Biochemistry and genetics of von Willebrand factor. , 1998, Annual review of biochemistry.

[40]  D. Wagner Cell biology of von Willebrand factor. , 1990, Annual review of cell biology.